BioXcel Therapeutics Inc
NASDAQ:BTAI

Watchlist Manager
BioXcel Therapeutics Inc Logo
BioXcel Therapeutics Inc
NASDAQ:BTAI
Watchlist
Price: 2.07 USD -0.96% Market Closed
Market Cap: 45.3m USD

Intrinsic Value

The intrinsic value of one BTAI stock under the Base Case scenario is 29.13 USD. Compared to the current market price of 2.07 USD, BioXcel Therapeutics Inc is Undervalued by 93%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BTAI Intrinsic Value
29.13 USD
Undervaluation 93%
Intrinsic Value
Price
Worst Case
Base Case
Best Case
Compare BTAI to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about BTAI?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
BioXcel Therapeutics Inc

Current Assets 44.4m
Cash & Short-Term Investments 36.2m
Other Current Assets 8.2m
Non-Current Assets 389k
PP&E 389k
Current Liabilities 37.8m
Accounts Payable 16.3m
Accrued Liabilities 4.3m
Other Current Liabilities 17.3m
Non-Current Liabilities 95.9m
Long-Term Debt 92.3m
Other Non-Current Liabilities 3.6m
Efficiency

Free Cash Flow Analysis
BioXcel Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
BioXcel Therapeutics Inc

Revenue
752k USD
Cost of Revenue
-964k USD
Gross Profit
-212k USD
Operating Expenses
-50.2m USD
Operating Income
-50.4m USD
Other Expenses
-17.8m USD
Net Income
-68.2m USD
Fundamental Scores

BTAI Profitability Score
Profitability Due Diligence

BioXcel Therapeutics Inc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROIC
Exceptional ROIC
Exceptional ROE
ROIC is Increasing
56/100
Profitability
Score

BioXcel Therapeutics Inc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

BTAI Solvency Score
Solvency Due Diligence

BioXcel Therapeutics Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
29/100
Solvency
Score

BioXcel Therapeutics Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BTAI Price Targets Summary
BioXcel Therapeutics Inc

There are no price targets for BTAI.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

BioXcel Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for BTAI is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

BTAI Insider Trading
Buy and sell transactions by insiders

BTAI News